Balyasny Asset Management
ARKG icon

Balyasny Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Balyasny Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-70,958
Closed -$1.47M – 2789
2025
Q1 		$1.47M Sell
70,958
-31,998
-31% -$804K ﹤0.01% 1840
2024
Q4 		$2.42M Buy
+102,956
New +$2.53M ﹤0.01% 1605
2021
Q1 		– Sell
-10,987
Closed -$1.02M – 1733
2020
Q4 		$1.02M Buy
+10,987
New +$875K 0.01% 1010

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Balyasny Asset Management's ARKG Position: Q2 2025 in Review

Balyasny Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2025, closing a stake of 70,958 shares — an estimated $1.47M sold.

Balyasny Asset Management first reported a position in ARKG in Q4 2020 and held it in 3 quarters. The position peaked at $2.42M in Q4 2024. 213 funds tracked by Wall St. Rank hold ARKG as of Q2 2025.

  • Balyasny Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 70,958 ARK Genomic Revolution ETF shares in Q2 2025, an estimated $1.47M.
  • Balyasny Asset Management first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 3 quarters.
  • Balyasny Asset Management's ARK Genomic Revolution ETF position peaked at $2.42M in Q4 2024.
  • 213 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.